Using the current World Health Organization threshold criteria, a new study examined whether osimertinib is cost-effective as a first-line therapy of EGFR-mutated advanced non-small cell lung cancer. READ MORE
News
Using the current World Health Organization threshold criteria, a new study examined whether osimertinib is cost-effective as a first-line therapy of EGFR-mutated advanced non-small cell lung cancer.
An economic model comparing different types of genetic testing in metastatic non-small cell lung cancer showed that next-generation sequencing is more cost-effective than testing for one or a limited number of genes at a given time.
Health care resource use and approaches to clinical management of advanced non-small cell lung cancer vary significantly in eight different countries.
Specific ALK variants may be linked to the development of ALK resistance mutations and poor clinical outcomes in patients with non-small cell lung cancer.
Resources
The National Comprehensive Cancer Network modified their guidelines for both non-small cell lung cancer and lung cancer screening to reflect new staging designations and testing results.
